Fate Therapeutics, Inc. income statement FATE

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, Fate Therapeutics, Inc. reported revenue of $0, down 100.0% from the same quarter a year earlier. It recorded a net loss of $30.7 million. Diluted earnings per share were -$0.25.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Revenue
5
-33.4%
0
-100.0%
2
+9.2%
1
-20.3%
1
-26.4%
2
-43.4%
2
-71.8%
2
-15.4%
2
+11.0%
Research and development
99
-14.9%
24
-6.3%
24
-11.1%
25
-15.2%
25
-24.4%
26
-25.4%
27
-20.7%
29
-9.3%
34
+5.6%
Selling, general and administrative
37
-27.4%
8
-24.5%
9
-22.9%
10
-30.3%
11
-30.1%
11
-48.9%
11
-33.7%
14
-34.0%
15
-14.9%
Operating income
-131
+25.0%
-32
+7.2%
-31
+15.8%
-33
+20.1%
-35
+43.8%
-35
+33.7%
-37
+18.0%
-41
+19.2%
-62
-28.4%
Net income
-124
+20.3%
-31
+4.8%
-30
+11.5%
-31
+17.0%
-32
+37.9%
-32
+32.4%
-34
+11.3%
-38
+21.6%
-52
-18.2%
Basic EPS
-1.03
+21.9%
-0.25
+7.4%
-0.25
+13.8%
-0.26
+18.8%
-0.27
+38.7%
-0.27
+32.5%
-0.29
+12.1%
-0.32
+31.9%
-0.44
+1.0%
Diluted EPS
-1.03
+21.9%
-0.25
+7.4%
-0.25
+13.8%
-0.26
+18.8%
-0.27
+38.7%
-0.27
+32.5%
-0.29
+12.1%
-0.32
+31.9%
-0.44
+1.0%
Weighted average shares, basic
121
+2.0%
124
+3.9%
120
+1.6%
120
+1.4%
119
+1.2%
119
+1.0%
119
+0.9%
118
+17.1%
118
+19.4%
Weighted average shares, diluted
121
+2.0%
124
+3.9%
120
+1.6%
120
+1.4%
119
+1.2%
119
+1.0%
119
+0.9%
118
+17.1%
118
+19.4%
Other measures
Depreciation and amortization
11
-21.9%
3
-17.0%
3
-15.2%
3
-12.5%
3
-36.4%
3
-30.0%
3
-30.6%
3
-30.9%
5
-1.5%
EBITDA
-120
+25.2%
-30
+6.2%
-28
+15.8%
-30
+20.7%
-32
+44.4%
-32
+34.0%
-34
+16.5%
-38
+17.9%
-57
-31.8%
Margins
Operating margin
-2,760.04%
—
-1,495.39%
-2,540.42%
-2,536.23%
-1,995.12%
-1,938.54%
-2,534.07%
-3,319.78%
Profit margin
-2,619.64%
—
-1,448.56%
-2,402.85%
-2,364.79%
-1,852.38%
-1,786.58%
-2,309.45%
-2,803.92%
EBITDA margin
-2,519.22%
—
-1,361.86%
-2,315.78%
-2,312.49%
-1,809.76%
-1,766.65%
-2,329.47%
-3,061.02%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
FATE (Nasdaq)
Fiscal year ends
December 31
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1434316

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.